Premenstrual Dysphoric Disorder

Clinical picture

• Symptoms emerge in the final week before menses, peak in the last few days, and remit within a few days after bleeding begins.
• Affective lability, irritability, and interpersonal conflict dominate the picture and are usually more prominent than sadness.
• Patients describe becoming a different person, with post-menstrual remorse about luteal-phase behavior toward partners and children.
• Physical complaints include breast tenderness, bloating, joint or muscle pain, headache, and marked appetite and food craving changes.
• Functional consequences are concrete: missed work, relationship rupture, and crisis contacts that cluster predictably within the cycle.
• Suicidal ideation can be cyclical and intense, with roughly a third of patients reporting luteal-phase suicidal thoughts.

Criteria snapshot

• At least five symptoms in most cycles of the past year, present in the final week before menses and remitting within days after onset.
• At least one core affective symptom is required: marked lability, irritability or anger, depressed mood or hopelessness, or anxiety and tension.
• Additional symptoms may include reduced interest, poor concentration, low energy, appetite change, sleep change, feeling overwhelmed, and physical symptoms.
• Diagnosis requires prospective daily ratings across at least two symptomatic cycles; a retrospective report alone yields only a provisional diagnosis.
• Symptoms must cause significant distress or interference and must not simply be a premenstrual exacerbation of another psychiatric disorder.

Neurobiology

• Ovarian steroid levels are normal; the disorder reflects abnormal central sensitivity to normal luteal fluctuation in estradiol and progesterone.
• Allopregnanolone, a progesterone metabolite and GABA-A receptor modulator, produces paradoxical anxiogenic responses in susceptible individuals.
• Serotonergic transmission is destabilized by gonadal steroid shifts, which explains the rapid, luteal-only therapeutic response to SSRIs.
• GnRH agonist suppression of ovulation abolishes symptoms and steroid add-back reinstates them, establishing hormone sensitivity as causal.
• Cellular studies of the ESC/E(Z) gene complex show altered transcriptional response to sex steroids in patient-derived lymphoblastoid cell lines.
• Heritability estimates approach 30 to 50 percent, with luteal-phase imaging showing amygdala hyperreactivity and reduced prefrontal regulation.

Psychology

• Cyclic predictability allows anticipatory dread, which amplifies symptom appraisal and can extend distress beyond the true luteal window.
• Interpersonal sensitivity and rejection appraisal sharpen premenstrually, converting minor slights into relationship-defining conflicts.
• Symptom tracking is itself therapeutic, restoring a sense of control and separating cyclical states from stable self-concept.
• Childhood trauma and chronic stress exposure increase risk, likely through stress-axis reactivity and heightened interpersonal sensitivity.
• Partner and family psychoeducation reduces attribution of luteal irritability to character, which lowers conflict escalation at home.

Differential & comorbidity

• Distinguish from premenstrual exacerbation of depression, bipolar disorder, or anxiety, in which symptoms persist through the follicular phase.
• Premenstrual syndrome is milder, lacks the required affective core symptom, and does not meet the same functional impairment threshold.
• Thyroid disease, perimenopause, anemia, and endometriosis can all mimic cyclical mood disturbance and somatic complaints.
• Comorbid major depression, anxiety disorders, and PTSD are common and should be treated concurrently rather than sequentially.
• Cyclic suicidality warrants explicit safety planning tied to cycle timing, including means restriction during high-risk luteal days.

Pharmacologic treatment

• SSRIs are first line and may be dosed continuously or luteal-phase only: sertraline 50-150 mg/day or fluoxetine 20 mg/day.
• Onset occurs within 1 to 2 days rather than the weeks required in major depression, which permits intermittent symptom-onset dosing.
• Combined oral contraceptives containing drospirenone on a 24/4 regimen are FDA-approved and reduce luteal affective and physical symptoms.
• GnRH agonists with estrogen and progestin add-back are reserved for refractory cases given bone density loss and vasomotor effects.
• Calcium 1200 mg daily has modest supportive evidence, while NSAIDs and spironolactone address pain, headache, and fluid retention.

Psychotherapy

• CBT adapted for PMDD reduces impairment and irritability, with gains that persist longer than medication effects after discontinuation.
• Prospective daily symptom charting across two cycles is simultaneously the diagnostic standard and the foundation of behavioral intervention.
• Interpersonal effectiveness and emotion regulation skills drawn from DBT target luteal conflict and impulsive behavior directly.
• Couples or family sessions reframe cyclical irritability as a treatable condition and build a shared plan for predictable high-risk days.
• Mindfulness-based approaches reduce reactivity to premenstrual physical sensations and to the affective shifts that accompany them.

Adjunct options

• Use the DRSP (Daily Record of Severity of Problems) to collect the two cycles of prospective rating that the diagnosis requires.
• Aerobic exercise, reduced caffeine and alcohol intake, and consistent sleep timing produce modest but reproducible symptom reduction.
• Schedule demanding work, travel, and difficult interpersonal conversations outside the luteal window whenever that is feasible.
• Hysterectomy with bilateral oophorectomy is definitive but a last resort, undertaken only after confirmed GnRH agonist response.
• Coordinate care with gynecology when hormonal contraception, GnRH suppression, or surgical management is under active consideration.

Clinical pearls

• No prospective two-cycle chart, no diagnosis; retrospective recall overdiagnoses PMDD.
• SSRIs act within a day or two here, which makes luteal-only dosing viable.
• Symptoms crossing into the follicular phase mean exacerbation, not PMDD.